Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Sprouts Farmers Market, Inc. due to allegations of misleading statements regarding the company's growth potential and sales performance, which may have led to investors purchasing securities at inflated prices [2][4]. Group 1: Legal Investigation and Class Action - Faruqi & Faruqi is encouraging investors who suffered losses in Sprouts between June 4, 2025, and October 29, 2025, to discuss their legal options [1]. - A federal securities class action has been filed against Sprouts, with a deadline of January 26, 2026, for investors to seek the role of lead plaintiff [2][6]. - The firm has a history of recovering hundreds of millions of dollars for investors since its establishment in 1995 [3]. Group 2: Financial Performance and Allegations - Sprouts reported a 4.3% decrease in comparable store growth in Q3 fiscal 2025, which was below previous projections [5]. - The company has revised its full-year sales growth expectations down from 7.5%-9% to 7%, attributing the shortfall to a cautious consumer environment [5]. - Allegations state that Sprouts executives made overly positive statements while concealing material adverse facts about the company's growth potential, leading to artificially inflated stock prices [4]. Group 3: Stock Market Impact - Following the disappointing Q3 results, Sprouts' stock price fell by $22.64, opening at $81.91 per share [5].

Core Viewpoint - Alexandria Real Estate Equities, Inc. is facing a securities class action lawsuit due to alleged failure to disclose material information during the class period, leading to significant financial losses for investors [3]. Group 1: Lawsuit Details - Investors who suffered substantial losses from purchasing Alexandria's securities between January 27, 2025, and October 27, 2025, have until January 26, 2026, to file lead plaintiff applications [1]. - The lawsuit is pending in the United States District Court for the Central District of California [1]. - The case is identified as Warren Hern v. Alexandria Real Estate Equities, Inc., et al., No. 25-cv-11319 [5]. Group 2: Financial Performance - On October 27, 2025, Alexandria disclosed third-quarter financial results for fiscal year 2025 that fell below expectations, including a reduction in full-year 2025 FFO guidance [4]. - The company reported a real estate impairment charge of $323.9 million, with $206 million attributed to its LIC property [4]. - Following this announcement, Alexandria's share price dropped from $77.87 to $62.94, marking a decline of approximately 19% in one day [5]. Group 3: Legal Representation - Kahn Swick & Foti, LLC, a prominent boutique securities litigation law firm, is representing the investors in this case [5]. - The firm has been recognized among the top 10 firms nationally based on total settlement value [5].

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Freeport-McMoran To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Freeport between February 15, 2022 and September 24, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK, Nov. 29, 2025 (GLOBE NEWSW ...

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Alexandria To Contact Him Directly To Discuss Their Options If you purchased or acquired Alexandria securities between January 27, 2025 to October 27, 2025 and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Melissa Forunato directly at (212) 355-4648. Click here to participate in the action. NEW YORK, Nov. 28, 2025 (GLOBE NEWSWIRE) -- What’s Happening: Bra ...

ARE SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Alexandria Real Estate EquitiesNovember 28, 2025 9:35 AM EST | Source: Faruqi & Faruqi LLPFaruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Alexandria To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in Alexandria between January 27, 2025 and October 27, 2025 and would like to discuss your legal rights ...

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Skye Biosciences, Inc. due to allegations of misleading statements regarding the effectiveness of its drug nimacimab, which led to significant financial losses for investors [2][5]. Group 1: Legal Investigation - The law firm is encouraging investors who suffered losses in Skye between November 4, 2024, and October 3, 2025, to discuss their legal options [1]. - A federal securities class action has been filed against Skye, with a deadline of January 16, 2026, for investors to seek the role of lead plaintiff [2][7]. - The firm has a history of recovering hundreds of millions of dollars for investors since its founding in 1995 [4]. Group 2: Allegations Against Skye - The complaint alleges that Skye and its executives violated federal securities laws by making false statements about nimacimab's effectiveness and overstating its clinical and commercial prospects [5]. - On October 6, 2025, Skye announced that its nimacimab did not achieve the primary endpoint of weight loss in a clinical study, leading to a 60% drop in stock price, closing at $1.90 per share [6]. Group 3: Investor Communication - Faruqi & Faruqi encourages anyone with information regarding Skye's conduct, including whistleblowers and former employees, to contact the firm [8].

Core Viewpoint - A class action lawsuit has been filed against Alexandria Real Estate Equities, Inc. (ARE) due to alleged misrepresentations regarding its LIC property, which has led to significant stock losses for investors [1][2]. Summary by Sections Lawsuit Announcement - The lawsuit, Warren Hern v. Alexandria Real Estate Equities, Inc., was initiated in the United States District Court for the Central District of California for investors who acquired ARE securities between January 27, 2025, and October 27, 2025 [1]. Allegations of Misrepresentation - The complaint claims that ARE did not possess reliable information about its leasing spreads, development tenant pipeline, and expected occupancy growth for its life-science properties, particularly the LIC property [2]. - It is asserted that the value and growth potential of the LIC property had been declining for years, rendering the company's optimistic reports about its development pipeline and occupancy rates misleading [2]. Investor Support and Compensation - The firm Levi & Korsinsky encourages affected ARE shareholders to come forward before the January 26, 2026 deadline to seek justice and potential compensation for their losses [3]. - Investors do not need to serve as lead plaintiffs to share in any recovery from the lawsuit [3]. Firm's Track Record - Levi & Korsinsky has a history of securing substantial compensation for shareholders and is recognized as one of the top securities litigation firms in the United States, with over 70 employees dedicated to serving clients [4].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Skye Biosciences, Inc. due to allegations of misleading statements regarding the effectiveness of its drug nimacimab, which led to significant stock price declines [2][5][6]. Group 1: Legal Investigation - The law firm is encouraging investors who suffered losses in Skye to contact them to discuss their legal options [1]. - A federal securities class action has been filed against Skye, with a deadline of January 16, 2026, for investors to seek the role of lead plaintiff [2][7]. - The firm has a history of recovering hundreds of millions of dollars for investors since its founding in 1995 [4]. Group 2: Allegations Against Skye - The complaint alleges that Skye and its executives violated federal securities laws by making false and misleading statements about nimacimab's effectiveness and overstating its clinical and commercial prospects [5]. - On October 6, 2025, Skye announced that nimacimab did not achieve its primary endpoint in a clinical study, leading to a 60% drop in stock price, closing at $1.90 per share [6]. Group 3: Investor Participation - Any member of the putative class can move the court to serve as lead plaintiff or choose to remain an absent class member, with no impact on their ability to share in any recovery [7]. - The firm is also seeking information from whistleblowers, former employees, and shareholders regarding Skye's conduct [8].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against WPP plc due to allegations of violations of federal securities laws related to misleading statements about the company's expected revenue for fiscal year 2025 [2][3]. Group 1: Allegations and Company Performance - The complaint alleges that WPP and its executives made false and misleading statements regarding the company's media division, claiming confidence in revitalization efforts while concealing the true challenges faced [2]. - WPP's trading update on July 9, 2025, indicated a deterioration in performance, attributing it to macroeconomic uncertainties and weaker new business than anticipated [3]. - Following the trading update, WPP's stock price dropped from $35.82 to $29.34, a decline of approximately 18.1% in one day [4]. Group 2: Legal Proceedings and Investor Actions - Investors who purchased WPP securities between February 27, 2025, and July 8, 2025, are encouraged to discuss their legal rights and options, with a deadline of December 8, 2025, to seek the role of lead plaintiff in the class action [1][5]. - The lead plaintiff is defined as the investor with the largest financial interest in the relief sought, who will oversee the litigation on behalf of the class [5]. - Faruqi & Faruqi, LLP is also seeking information from whistleblowers, former employees, and shareholders regarding WPP's conduct [6].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Molina Healthcare, Inc. due to alleged violations of federal securities laws, with a deadline for investors to seek lead plaintiff status by December 2, 2025 [1][3]. Group 1: Allegations Against Molina - The complaint alleges that Molina and its executives made false or misleading statements regarding the company's medical cost trend assumptions and failed to disclose adverse facts affecting its financial outlook [3]. - Specific issues cited include a dislocation between premium rates and medical costs, reliance on low utilization of services, and the likelihood of substantial cuts to financial guidance for fiscal year 2025 [3]. Group 2: Financial Performance and Stock Impact - On July 7, 2025, Molina announced second-quarter results, reporting adjusted earnings of approximately $5.50 per share, which was below expectations, leading to a 10.2% cut in full-year earnings guidance from at least $24.50 to a range of $21.50 to $22.50 per share [4]. - Following this announcement, Molina's stock price fell by $6.97, or 2.9%, closing at $232.61 per share on July 7, 2025 [4]. - On July 23, 2025, Molina further reduced its full-year earnings guidance, reporting GAAP net income of $4.75 per diluted share for the second quarter, an 8% decrease year-over-year, and cutting guidance for full-year adjusted earnings to no less than $19.00 per diluted share, a 13.6% reduction [5]. - This led to a significant drop in Molina's stock price by $32.03, or 16.84%, closing at $158.22 per share on July 24, 2025 [5].